Newron: ENIGMA-TRS trials to unravel the role of evenamide in TRS

Monday, May 12, 2025 @ 12:00 am

Newron received approval for its pivotal ENIGMA-TRS development program for evenamide in TRS, consisting of two phase III trials in over 1,000 patients. This improves the regulatory risk compared to the initial plan for a single pivotal trial with fewer patients, provided both phase III trials yield positive results.

Key catalysts include:

Start of pivotal “ENIGMA-TRS” phase III trial (imminently)
H1 2025 results (16 Sep 2025)
Partnering evenamide in non-core markets (during 2025)

Newron Flash Update

You may also be interested in

Swiss Biotech Report 2025 highlights sector’s continuing resilience through commitment to international alliances

Total revenues remain strong at CHF 7.2 billion (CHF 7.3 billion in 2023) Record CHF 833 million raised by privately funded companies drives 22% overall rise in capital investment to CHF 2.5 billion (CHF 2.0 billion in 2023) Alentis Therapeutics (CHF 163 million) and SixPeaks Bio (CHF 102 million) lead the way in the private financing rounds Despite market headwinds, some public companies report n
May 6, 2025

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Umlaut.bio: First-in-biology approach for therapies targeting tRNA modifications

First characterization of tRNA modifications that dysregulate mRNA stability of signaling pathways in cancer Umlaut.bio is an EMBL spin-off creating cancer and autoimmune therapeutics through small molecule inhibition of tRNA modifications With its senior executive team and a world-class advisory board, Umlaut.bio has started operations funded by HTGF, LBBW Venture Capital and L-Bank through the I
May 13, 2025

ten23 health: Robot-assisted pilot non-GMP sterile filling

Customers can now accelerate new product development with early access to non-GMP but clinically representative liquid and lyophilized batches. The pilot line is easy to access, reduces costs, and allows the use of material that would not be suitable for GMP processing.
May 12, 2025

Nagi Bioscience: Expansion into South Korean market through strategic partnership with Rhino Bio

Nagi Bioscience, a pioneering Swiss company specializing in cutting-edge laboratory technologies for alternative model organisms research, announced a strategic partnership with Rhino Bio Inc., a leading distributor for next–generation analytical systems in South Korea. The partnership accelerates Nagi Bioscience’s expansion into the South Korean market, driven by strong demand for its flagshi
May 7, 2025

SIX Swiss Exchange talks to: Basilea on how it strengthened its market position in 2024

Christian Moser Nikles, Patent Expert & Christel Aebischer, Patent Expert | Swiss Federal Institute of Intellectual Property
SIX Swiss Exchange reviews publicly listed companies included in ‘Highlights of 2024: Year in Review’ (Pages 52 to 55). While Santhera and Kuros made good progress, SIX recognizes the notable success of Basilea which, 20 years after its IPO in 2004, has reported increasingly robust profits.
May 5, 2025